Table 1 Patient characteristics.

From: Pharmacogenetics-Guided Phase I Study of Capecitabine on an Intermittent Schedule in Patients with Advanced or Metastatic Solid Tumours

Age

 Median (range)

58

 Range

34–74

Gender

 Female

13 (56.5%)

 Male

10 (43.5%)

Ethnicity

 Chinese

17 (73.9%)

 Malay

4 (17.4%)

 Indian

2 (8.7%)

Primary tumour

 Breast

11 (47.8%)

 Colorectal

6 (26.1%)

 Laryngeal & nasopharyngeal

2 (8.7%)

 Hepatocellular & pancreatic

2 (8.7%)

 Gastric & carcinoid

2 (8.7%)

Disease sites (target + non-target)

 Median

5

 Range

1–12

Prior treatment

 Chemotherapy

No previous treatment

3 (13.0%)

1 regimen

10 (43.5%)

2 regimens

3 (13.0%)

≥3 regimens

7 (30.4%)

Hormonal therapy

9 (39.1%)

Surgery

15 (65.2%)

Radiotherapy

13 (56.5%)

Creatinine clearance (mL/min/1.73 m2)

 Mean ± SD

106 ± 30.9